 Heidelberg, Germany and Santa Ana, Calif., March 31, 2021 - Affimed N.V. NASDAQ: AFMD, a clinical-stage immuno-oncology company, and NKMax America Inc., a clinical stage biotech company, announced today that the U.S. Food and Drug Administration FDA cleared an investigational new drug application IND for an Affimed and NKMax America co-sponsored Phase 12a dose escalation and expansion study in which the two companies will investigate the combination of AFM24, an EGFRCD16A innate cell engager ICE, and SNK-01, an autologous NK-cell product, in patients suffering from tumors known to express EGFR. The combination represents a novel approach to exploring innate immunity-based therapeutics to treat patients with solid tumors who failed conventional therapy with the aim to improve outcomes for high-medical need patient populations. 